Prospective Study
Copyright ©The Author(s) 2015.
World J Cardiol. Dec 26, 2015; 7(12): 922-930
Published online Dec 26, 2015. doi: 10.4330/wjc.v7.i12.922
Table 1 Study population
Clinical characteristics of the study population
Age (yr)70.3 ± 8.3
Male (%)78.3
EF (%)27.5 ± 6.5
Etiology post-ischemic DC (%)63.2
Idiopathic DC (%)33.7
Valvular DC (%)2
Congenital DC (%)1.1
NYHA II (%)17.3
III (%)78.6
IV (%)4.1
Optimized pharmacological treatment (%)63.21
Prevention: Primary (%)73.7
Secondary (%)18.3
SVT (%)3.7
Syncope (%)3.2
Cardiac arrest (%)5.1
AF permanent (%)16.3
Persistent (%)7.4
Paroxysmal (%)4.1
Devices: Consulta™ CRT-D37.4
Concerto™ II CRT-D (%)26.3
Viva XT™ CRT-D (%)22.1
Protecta XT™ CRT-D (%)14.2
Table 2 Pharmacological treatment modifications following positive or negative partners-heart failure transmissions and care alert
Active clinical actionsPartners-HF +Care alert +
Pharmacological treatment modification during telephonic contact
Diuretic dosage increase12025
BB dosage increase5722
AAD administration22
ACE-I and ARA dosage increase40
OAC administration55
Clinical examination and pharmacological treatment modification
Diuretic dosage increase94
BB dosage increase83
AAD administration11
ACE-I and ARA dosage increase11
Anti-platelet administration00
Table 3 Diagnostic accuracy of partners-heart failure and care alert in determining active clinical actions
Active clinical actions (2-3)Non-active/no clinical actions (0-1)Total transmissions
Positive partners-HF transmissions19335228
Negative partners-HF transmissions6431437
Positive care alert transmissions223052
Negative care alert transmissions177436613
Overall transmissions followed by an action199466665
Appendix partners-HF algorithm
ParametersCriterion
Fluid index≥ 60 d
AT/AF duration≥ 6 h and not persistent AT/AF
VR during AT/AFAT/AF ≥ 24 h and VR ≥ 90 bpm
Patient activity< 1 h over 1 wk
NHR≥ 85 bpm for 7 consecutive days
HRV< 60 ms for 7 consecutive days
%CRT pacing< 90% for 5 of 7 d
Shock (s)≥ 1 shock